Therapeutical Class：1st generation cephalosporins, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): variable against β-lactamase producing Staphylococci and Neisseria, not for Enterococci and MRSA; G(-): E. coli, P. mirabilis, some Klebsiella.

Administraton：PO

Adults: 250 mg-1g q6h, max 4 g/day.

Cellulitis: 500 mg q6h.

Uncomplicated cystitis, Streptococcal pharyngitis, skin and skin structure infections: 500 mg q12h.

Children >1 yr: 25-100 mg/kg/day q6h;

Severe infection: 50-100 mg/kg/day q6h, max 4 g/day.

Renal impairment: Ccr 10-50 ml/min, 500 mg q8-12 h;

Ccr <10 ml/min, 250-500 mg q12-24h.

Adverse Effect：Allergy (rash, etc.), diarrhea, nausea, vomiting, eosinophilia, leucopenia, hemolytic anemia, seizures, headache, tinnitus, pseudomembranous colitis, urticaria, dermatitis, drug fever.

Pregnancy Risk：BSupply：Ceflexin XE “Ceflexin”  Cap 500mg(賜復力生膠囊 榮民) ＜00267＞